Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acelyrin Inc (NQ: SLRN )

5.980 -0.140 (-2.29%)
Streaming Delayed Price Updated: 10:07 AM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acelyrin Inc

< Previous 1 2 3 4 Next >
NASDAQ:SLRN Investor Notice: Investigation over Potential Wrongdoing at Acelyrin, Inc.
San Diego, CA -- (SBWIRE) -- 10/31/2023 -- Certain directors of Acelyrin, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
NASDAQ:SLRN Shareholder Notice: Investigation over Possible Securities Laws Violations by Acelyrin, Inc.
San Diego, CA -- (SBWIRE) -- 10/06/2023 -- An investigation was announced over potential securities laws violations by Acelyrin, Inc in connection with certain financial statements. 
Via SBWire
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
From Acelyrin, Inc.
Via GlobeNewswire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Acelyrin Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
From Acelyrin, Inc.
Via GlobeNewswire
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Acelyrin, Inc.
Via GlobeNewswire
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
From Acelyrin, Inc.
Via GlobeNewswire
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
From Acelyrin, Inc.
Via GlobeNewswire
ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer
From Acelyrin, Inc.
Via GlobeNewswire
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
From Acelyrin, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.